AFP and cholangiocarcinoma: At one year after RA/LFUR, compared with at 6 months after the treatment, ALT, AST, TBIL and Alb changed insignificantly, and AFP increased minimally (3.6±1.5 vs 7.2 ng/mL, t = 1.54, P>0.05) in a patient with CC who experienced cancer recurrence and increased significantly (6.9±2.4 vs 305.5±3.7 ng/mL, t = 51.36, P<0.05) in a patient with HCC who developed intrahepatic metastasis.